Evidence map›Paper›PMID 33752085›Full record

ReviewJournal of hazardous materials2021

Can ozone inactivate SARS-CoV-2? A review of mechanisms and performance on viruses.

Bernardí Bayarri, Alberto Cruz-Alcalde, Núria López-Vinent, María M Micó, Carme Sans

Abstract readReview
In one paragraph

Review in Journal of hazardous materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Advances in Ozone-Based Inactivation of SARS-CoV-2: An Updated Review.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Bernardí BayarriDepartment of Chemical Engineering and Analytical Chemistry, Faculty of Chemistry, Universitat de Barcelona, C/Martí i Franqués 1, 08028 Barcelona, Spain. Electronic address: bbayarri@ub.edu.
Alberto Cruz-AlcaldeDepartment of Chemical Engineering and Analytical Chemistry, Faculty of Chemistry, Universitat de Barcelona, C/Martí i Franqués 1, 08028 Barcelona, Spain.
Núria López-VinentDepartment of Chemical Engineering and Analytical Chemistry, Faculty of Chemistry, Universitat de Barcelona, C/Martí i Franqués 1, 08028 Barcelona, Spain.
María M MicóDepartment of Chemical Engineering and Analytical Chemistry, Faculty of Chemistry, Universitat de Barcelona, C/Martí i Franqués 1, 08028 Barcelona, Spain.
Carme SansDepartment of Chemical Engineering and Analytical Chemistry, Faculty of Chemistry, Universitat de Barcelona, C/Martí i Franqués 1, 08028 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has challenged societies around the globe. Technologies based on ozone, a powerful oxidant, have been evaluated to inactivate this virus in aerosols and fomites. However, the high data diversity hinders the possibility of establishing a common ground for determining best practices for the use of these technologies. Furthermore, there is a lack of consensus regarding which are the main mechanisms of ozone virus inactivation. This critical review examined the most relevant information available regarding ozone application in gas-phase for different viruses inactivation (including recent publications dealing with SARS-CoV-2), and pointed towards envelope alteration as the main reaction pathway for enveloped viruses, such as is the case of SARS-CoV-2. It could also be concluded that gaseous ozone can be indeed an effective disinfectant, successfully inactivating viruses such us influenza A H1N1, MERS-CoV, SARS-CoV-1 or even SARS-CoV-2 in aerosols or fomites. In reviewed works, low ozone exposures, just around 0.1-0.4 mg L

Indexed as

COVID-19Influenza A Virus, H1N1 SubtypeOzoneHumansSARS-CoV-2Virus InactivationOzoneAerosolsCOVID-19Enveloped virusesFomitesInactivationOzonationSARS-CoV-2

Identifiers

PMID33752085
PMCPMC7955572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.